Sun Pharmaceutical Industries Ltd. - Research Center
524715 SUNPHARMA Group (A) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 20 | Mar ' 19 | Mar ' 18 | Mar ' 17 | Mar ' 16 | |
|---|---|---|---|---|---|
| Sales | 12,531.93 | 10,303.21 | 7,947.60 | 7,806.70 | 7,863.69 |
| Operating profit | 2,711.65 | 1,756.26 | 123.02 | 95.27 | -418.67 |
| Interest | 408.01 | 540.92 | 388.31 | 223.56 | 574.10 |
| Gross profit | 3,814.56 | 2,486.78 | 862.75 | 386.12 | -547.68 |
| EPS (Rs) | 13.38 | 3.40 | -2.06 | -0.15 | -4.52 |
Annual
results in details
| Mar ' 20 | Mar ' 19 | Mar ' 18 | Mar ' 17 | Mar ' 16 | |
|---|---|---|---|---|---|
| Other income | 1,510.92 | 1,271.44 | 1,128.04 | 514.41 | 445.09 |
| Stock adjustment | 138.60 | -251.30 | 159.26 | -162.79 | -14.38 |
| Raw material | 3,201.71 | 2,727.71 | 2,167.52 | 2,284.52 | 1,838.31 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 1,702.77 | 1,571.34 | 1,617.69 | 1,486.17 | 1,476.69 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 4,777.20 | 4,499.20 | 3,880.11 | 4,103.53 | 4,981.74 |
| Provisions made | - | - | - | - | - |
| Depreciation | 561.56 | 552.95 | 432.23 | 418.56 | 464.25 |
| Taxation | 41.86 | -97.15 | -25.39 | 2.51 | 5.45 |
| Net profit / loss | 3,211.14 | 816.60 | -494.59 | -34.95 | -1,087.51 |
| Extra ordinary item | - | -1,214.38 | -950.50 | - | -70.13 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 239.93 | 239.93 | 239.93 | 239.93 | 240.66 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 21.64 | 17.05 | 1.55 | 1.22 | -5.32 |
| GPM (%) | 27.16 | 21.48 | 9.51 | 4.64 | -6.59 |
| NPM (%) | 22.87 | 7.06 | -5.45 | -0.42 | -13.09 |
© 2020 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis